studies Study Report - GWAS of bipolar disorder in a British population (HGVST7)
bookmark Bookmark
  Change.. ) goto Explore Study in Browser 
Export Study as: 
Identifier HGVST7
Study name GWAS of bipolar disorder in a British population
Total p-values imported 95
Phenotype(s) tested
Bipolar disorder
Study design Case and control
Genotype platforms Affymetrix 500K Gene Chip
Abstract Summary-level data and analysis results of Biopolar Disorder (BD) imported from the Wellcome Trust Case Control Consortium project
Submission information
ContributorDate
Submitted
Author? Submitter? Source?
WTCCC1 2009-03-30 yes no yes
HGVbaseG2P 2009-03-30 no yes no
Author communication info
Corresponding author Date of contact Response received Date of response Type of response info
Peter Donnelly 2011-03-17 no -- --
2012-01-18 no -- --
Related links WTCCC1link
Background The Wellcome Trust Case Control Consortium (WTCCC) was formed with a view to exploring the utility, design and analyses of GWA studies. It brought together over 50 research groups from the UK that are active in researching the genetics of common human diseases, with expertise ranging from clinical, through genotyping, to informatics and statistical analysis. Bipolar disorder (BD; manic depressive illness) refers to an episodic recurrent pathological disturbance in mood (affect) ranging from extreme elation or mania to severe depression and usually accompanied by disturbances in thinking and behaviour: psychotic features (delusions and hallucinations) often occur. Pathogenesis is poorly understood but there is robust evidence for a substantial genetic contribution to risk  
Objectives The main experiment consisted of a GWA study of 2,000 cases and 3,000 shared controls for a complex human disease of major public health importance, bipolar disorder (BD). By simultaneously studying bipolar disorder (BD) with other diseases with differing aetiologies, we hoped to develop in sights, not only into the specific genetic contributions to each of the diseases, but also into differences in allelic architecture across the diseases. A further major aim was to address important methodological issues of relevance to all GWA studies, such as quality control, design and analysis. In addition to our main association results, we address several of these issues below, including the choice of controls for genetic studies, the extent of population structure within Great Britain, sample sizes necessary to detect genetic effects of varying sizes, and improvements in genotype-calling algorithms and analytical methods.
Key results The strongest signal in BD was with rs420259 at chromosome 16p12 (genotypic test P = 6.3x10-8) and the best-fitting genetic model was recessive. Amongst the other higher ranked signals in the BD data set there is support for the previously suggested importance of GABA neurotransmission (rs7680321 (P = 6.2x10-5) in GABRB1 encoding a ligand-gated ion channel (GABA A receptor, beta 1)), glutamate neurotransmission (rs1485171 (P = 9.7x10-5) in GRM7 (glutamate receptor, metabotropic 7)) and synaptic function (rs11089599 (P = 7.2x10-5) in SYN3 (synapsin III)).
Conclusions Not supplied
Reason for study size Not supplied
Study power Not supplied
Sources of bias Not supplied
Limitations Not supplied
Acknowledgements The principal funder of this project was the Wellcome Trust. Please see publication for the full list of acknowledgements.
Related citations
The Wellcome Trust Case Control Consortiumlink
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls.
Nature 2007 Jun 7;447(7145):661-78